Search
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.
Products: ALPROLIX® 250 UIHuman papillomavirus type 18 L1 capsid protein antigen
go.drugbank.com/drugs/DB10302ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETMK-8777
go.drugbank.com/drugs/DB18904InvestigationalMK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder … (174001/P05704/MK-8777-001)).
Synonyms: 5H,7H-PYRIDO(3,2-F)PYRROLO(2,1-C)(1,4)OXAZEPIN-5-ONE, 8,9,9A,10-TETRAHYDRO-, (9AS)-Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Mixtures: VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADET, FluQuadri Quadrivalent Influenza Vaccine, 0.25 mlOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: -c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dim, 3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results
Synonyms: 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinonePivhydrazine
go.drugbank.com/drugs/DB09252ApprovedWithdrawnIn 1960, it was widely used as an antidepressant agent but it is now discontinued.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMeningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesMargetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986] … Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative